These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2756691)

  • 1. [Sermion treatment of middle-aged and elderly patients with initial atherosclerotic encephalopathy].
    Man'kovskiĭ NB; Mints AIa; Bachinskaia NIu; Kochubeĭ NV
    Vrach Delo; 1989 Apr; (4):60-3. PubMed ID: 2756691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effect of sermion on the main hemodynamic indices in patients with the initial manifestations of cerebral atherosclerosis].
    Tokar' AV; Akhaladze NG; Ena LM; Rudaia ES; Severova NL
    Vrach Delo; 1990 Feb; (2):27-30. PubMed ID: 2339544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Use of sermion in cerebral atherosclerosis patients with a history of ischemic stroke].
    Tsimenko OA; Sosnov IuD; Kharchenko AP; Gaĭduk IuS
    Vrach Delo; 1988 Jul; (7):24-7. PubMed ID: 3188456
    [No Abstract]   [Full Text] [Related]  

  • 4. [The dynamics of the cerebral circulation and of brain functional activity in patients with initial atherosclerotic encephalopathy under the influence of a single intravenous administration of sermion].
    Mints AIa; Karaban' IN; Litvinenko AA
    Farmakol Toksikol; 1991; 54(4):59-62. PubMed ID: 1786832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Initial dyscirculatory encephalopathy in middle-aged and elderly patients (problems of early diagnosis and therapy)].
    Man'kovskiĭ NB; Mints AIa; Karaban' IN
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1989; 89(1):16-20. PubMed ID: 2718657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The effect of sermion on brain function in diabetics].
    Efimov AS; Man'kovskiĭ BN
    Vrach Delo; 1991 Nov; (11):73-6. PubMed ID: 1801441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Electroencephalography and psychometric measurements during the treatment of cerebral insufficiency with nicergoline and dihydroergotamine mesylate].
    Kugler JE; Meurer-Krüll BC
    Arzneimittelforschung; 1985; 35(12):1865-70. PubMed ID: 3913425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The correction of microcirculatory disorders in patients with circulatory encephalopathy].
    Vesel'skiĭ ISh; Sanik AV
    Vrach Delo; 1991 Jul; (7):85-7. PubMed ID: 1771847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Action of Nicergoline (Sermion) in chronic vascular disease in old age].
    Michelangeli J; Sevilla M; Lavagna J; Darcourt G
    Ann Med Psychol (Paris); 1975 Apr; 1(4):499-510. PubMed ID: 788599
    [No Abstract]   [Full Text] [Related]  

  • 10. [The role of nicergoline in the symptomatic treatment of arterial hypertension and chronic cerebrovascular insufficiency. A study on 359 observations (author's transl)].
    Dauverchain J
    Arzneimittelforschung; 1979; 29(8a):1308-10. PubMed ID: 395956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current treatment of cerebrovascular disorder with vasoactive drugs].
    Lebiediewa NW
    Neurol Neurochir Pol; 1981; 15(4):417-21. PubMed ID: 6895779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Polygraphic evaluation of a new vasoactive drug (nicergoline)].
    Baturic P; Cirignotta F
    Minerva Cardioangiol; 1973 Oct; 21(10):664-7. PubMed ID: 4589189
    [No Abstract]   [Full Text] [Related]  

  • 13. [Neurophysiological study of 36 patients with cerebral vascular processes treated with nicergoline (author's transl)].
    Samsó Dies JM; Villa Badó J; Villalobos J; Iriarte JL; Ordeix R
    Arzneimittelforschung; 1979; 29(8a):1301-7. PubMed ID: 540075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapy of demonstrated cerebral ischemia with nicergoline (Sermion)].
    Karyofilis A
    Ther Ggw; 1980 Dec; 119(12):1478-85. PubMed ID: 7466692
    [No Abstract]   [Full Text] [Related]  

  • 15. [Evaluation of the effectiveness and tolerance of the preparation Sermion in the treatment of selected retinal diseases].
    Szaflik J; Jupowiecka A
    Klin Oczna; 1985 Apr; 87(4):165-6. PubMed ID: 3900547
    [No Abstract]   [Full Text] [Related]  

  • 16. [Use of nicergoline (Sermion) in the treatment of migraine].
    Prusiński A; Durko A; Selmaj K
    Wiad Lek; 1984 Mar; 37(6):420-2. PubMed ID: 6385484
    [No Abstract]   [Full Text] [Related]  

  • 17. [Interaction between anti-aggregating and anticoagulant agents. A double blind study on the concomitant administration of nicergoline and acenocoumarols].
    Pogliani E; Recalcati P; Tantalo V; Bregnani P
    Arzneimittelforschung; 1979; 29(8a):1266-9. PubMed ID: 395954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Nicergoline and cerebral performance insufficiency. Observations in 1 year treatment controls].
    Kugler J; Heidrich H
    Fortschr Med; 1984 Nov; 102(42):1091-6. PubMed ID: 6392047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of arterial hypertension in the elderly with an alpha-blocker: nicergoline (author's transl)].
    Forette F; Varin D; Henry JF; Hervy MP
    Nouv Presse Med; 1980 Dec; 9(48):3685-8. PubMed ID: 7005872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical use of a new vasoactive drug : nicergoline].
    Mellini M
    Minerva Med; 1973 May; 64(34):1844-53. PubMed ID: 4719381
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.